Zimmer Partners, LP Blueprint Medicines Corp Transaction History

Zimmer Partners, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$86.69 - $115.63 $2.08 Million - $2.78 Million	-24,030 Reduced 71.41%	9,620 $851,000
Q4 2024 Feb 14, 2025	BUY	$82.48 - $101.39 $1.04 Million - $1.27 Million	12,550 Added 59.48%	33,650 $2.93 Million
Q3 2024 Nov 14, 2024	BUY	$84.1 - $120.5 $1.77 Million - $2.54 Million	21,100 New	21,100 $1.95 Million
Q2 2023 Aug 14, 2023	BUY	$42.2 - $66.37 $1.2 Million - $1.88 Million	28,400 New	28,400 $1.79 Million

389

66.9M

973K

1.54M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $7.73B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Zimmer Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Zimmer Partners, LP with notifications on news.